Copyright Nasdaq. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna to Present at Rodman & Renshaw 19th Annual Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the Rodman & Renshaw...
View HTML
Toggle Summary Dicerna Reports Second Quarter 2017 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the second quarter...
View HTML
Toggle Summary Dicerna to Report Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2017 financial results after market close on Thursday, August...
View HTML
Toggle Summary Dicerna Expands Lead GalXC™ Development Program to Encompass All Forms of Primary Hyperoxaluria (PH) and Reveals New Therapeutic Target for DCR-PHXC
DCR-PHXC Achieved Broad, Durable, and Consistent Knockdown of LDHA and Reduction of Oxalate in Multiple Animal Models of PH New Data Presented at 12 th International PH Workshop Also Include Update from PHYOS Trial of Patients with PH1 Management to Host Conference Call Today at 10:00 a.m....
View HTML
Toggle Summary Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that based on recommendations from the Compensation Committee of the Company's Board of Directors, on June 7,...
View HTML
Toggle Summary Dicerna Announces Appointment of Ralf Rosskamp, M.D., as Chief Medical Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of industry veteran Ralf Rosskamp , M.D., as chief medical officer, effective June 15, 2017 ....
View HTML
Toggle Summary Dicerna to Present at Jefferies 2017 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the Jefferies 2017...
View HTML
Toggle Summary Dicerna Reports First Quarter 2017 Financial and Operational Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operational results for the first quarter...
View HTML
Toggle Summary Dicerna to Report First Quarter 2017 Financial Results and Host Conference Call on May 8, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2017 financial results after market close on Monday, May 8,...
View HTML
Toggle Summary Dicerna Announces Closing of $70 Million Convertible Preferred Stock Financing
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company"), a leading developer of investigational ribonucleic acid interference ("RNAi") therapeutics, today announced that it has closed its previously announced stock purchase transaction for the sale of...
View HTML